Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/UCART19> ?p ?o }
Showing triples 1 to 25 of
25
with 100 triples per page.
- UCART19 abstract "An experimental immunotherapy against leukemia using genetically modified T-cells developed by Cellectis. Unlike personalized medicine, UCART19 is hoped to be “off-the-shelf”. Developed for Chronic lymphocytic leukemia (CLL) and Acute lymphoblastic leukemia (ALL)".
- UCART19 wikiPageID "48478624".
- UCART19 wikiPageLength "844".
- UCART19 wikiPageOutDegree "8".
- UCART19 wikiPageRevisionID "697694090".
- UCART19 wikiPageWikiLink Acute_lymphoblastic_leukemia.
- UCART19 wikiPageWikiLink Adoptive_cell_transfer.
- UCART19 wikiPageWikiLink B-cell_chronic_lymphocytic_leukemia.
- UCART19 wikiPageWikiLink Category:Cell_biology.
- UCART19 wikiPageWikiLink Category:Immunology.
- UCART19 wikiPageWikiLink Cellectis.
- UCART19 wikiPageWikiLink Chimeric_antigen_receptor.
- UCART19 wikiPageWikiLink Immunotherapy.
- UCART19 wikiPageUsesTemplate Template:Med-stub.
- UCART19 wikiPageUsesTemplate Template:Multiple_issues.
- UCART19 wikiPageUsesTemplate Template:Notability.
- UCART19 wikiPageUsesTemplate Template:Orphan.
- UCART19 wikiPageUsesTemplate Template:Refimprove.
- UCART19 wikiPageUsesTemplate Template:Reflist.
- UCART19 subject Category:Cell_biology.
- UCART19 subject Category:Immunology.
- UCART19 comment "An experimental immunotherapy against leukemia using genetically modified T-cells developed by Cellectis. Unlike personalized medicine, UCART19 is hoped to be “off-the-shelf”. Developed for Chronic lymphocytic leukemia (CLL) and Acute lymphoblastic leukemia (ALL)".
- UCART19 label "UCART19".
- UCART19 wasDerivedFrom UCART19?oldid=697694090.
- UCART19 isPrimaryTopicOf UCART19.